biostudies-literatureUnknown4(2)Hofman V<h4>Introduction</h4>Gene fusion testing of <i>ALK</i>, <i>ROS1</i>, <i>RET</i>, <i>NTRK</i>, and <i>MET</i> exon 14 skipping mutations is guideline recommended in nonsquamous NSCLC (NS-NSCLC). Nevertheless, assessment is often hindered by the limited availability of tissue and prolonged next-generation sequencing (NGS) testing, which can protract the initiation of a targeted therapy. Therefore, the development of faster gene fusion assessment is critical for optimal clinical decision-making. Here, we compared two ultrafast gene fusion assays (UFGFAs) using NGS (Genexus, Oncomine Precision Assay, Thermo Fisher Scientific) and a multiplex reverse-transcriptase polymerase chain reaction (Idylla, GeneFusion Assay, Biocartis) approach at diagnosis in a retrospective series of 195 NS-NSCLC caseJTO clinical and research reports100457https://www.ebi.ac.uk/biostudies/studies/S-EPMC9883235biostudies-literatureUltrafast Gene Fusion Assessment for Nonsquamous NSCLC.PMC9883235Evrard SMarquette CHBegueret HAllegra MCaumont CBarritault MVigier ABrousset PBenzerdjeb NLespinet-Fabre VBordone OBoutros JSalah MBontoux CBenzaquen JTanga VBringuier PPFenouil TChalabreysse LHeeke SHofman PHofman VMerlio JPSabourin JCLassalle SIlie MLong-Mira ESyrykh CMazieres JBonnetaud CPiton NfalseUltrafast Gene Fusion Assessment for Nonsquamous NSCLC.<h4>Introduction</h4>Gene fusion testing of <i>ALK</i>, <i>ROS1</i>, <i>RET</i>, <i>NTRK</i>, and <i>MET</i> exon 14 skipping mutations is guideline recommended in nonsquamous NSCLC (NS-NSCLC). Nevertheless, assessment is often hindered by the limited availability of tissue and prolonged next-generation sequencing (NGS) testing, which can protract the initiation of a targeted therapy. Therefore, the development of faster gene fusion assessment is critical for optimal clinical decision-making. Here, we compared two ultrafast gene fusion assays (UFGFAs) using NGS (Genexus, Oncomine Precision Assay, Thermo Fisher Scientific) and a multiplex reverse-transcriptase polymerase chain reaction (Idylla, GeneFusion Assay, Biocartis) approach at diagnosis in a retrospective series of 195 NS-NSCLC case2023-01-01T00:00:00Z2023 Feb2025-04-21T22:37:00.483Z2025-04-05T18:48:54.443ZS-EPMC98832353671814010.1016/j.jtocrr.2022.100457